The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Retinal Degenerative Disease Treatment Market Research Report 2024

Global Retinal Degenerative Disease Treatment Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1743618

No of Pages : 107

Ask Your Query

Synopsis
Global Retinal Degenerative Disease Treatment market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Retinal Degenerative Disease Treatment market research.

Key companies engaged in the Retinal Degenerative Disease Treatment industry include Sucampo Pharmaceuticals, Vivani Medical(Second Sight Medical), Roche, ReNeuron, ReGenX Biosciences, Regeneron Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Okuvision and Ocugen, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Retinal Degenerative Disease Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Retinal Degenerative Disease Treatment market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Retinal Degenerative Disease Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Sucampo Pharmaceuticals
  • Vivani Medical(Second Sight Medical)
  • Roche
  • ReNeuron
  • ReGenX Biosciences
  • Regeneron Pharmaceuticals
  • Orphagen Pharmaceuticals, Inc.
  • Okuvision
  • Ocugen
  • Novartis
  • Nano Retina
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Kanghong Pharma
  • Ionis Pharmaceuticals, Inc.
  • International Stem Cell Corporation
  • InFlectis BioScience
  • Grupo Ferrer Internacional, S.A.
  • GenSight Biologics S.A.
  • Genethon
  • Genable Technologies Limited
  • Dompe Farmaceutici S.p.A.
  • Caladrius Biosciences, Inc.
  • Bayer HealthCare
  • Astellas Pharma Inc.
  • Amarantus BioScience

Segment by Type

  • Age Related Macular Degeneration (AMD) Treatment
  • Retinitis Pigmentosa (RP) Treatment

Segment by Application

  • 20 to 60 Years Old
  • 60 and Over
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Retinal Degenerative Disease Treatment report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Retinal Degenerative Disease Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Age Related Macular Degeneration (AMD) Treatment
1.2.3 Retinitis Pigmentosa (RP) Treatment
1.3 Market by Application
1.3.1 Global Retinal Degenerative Disease Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 20 to 60 Years Old
1.3.3 60 and Over
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Retinal Degenerative Disease Treatment Market Perspective (2018-2029)
2.2 Retinal Degenerative Disease Treatment Growth Trends by Region
2.2.1 Global Retinal Degenerative Disease Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Retinal Degenerative Disease Treatment Historic Market Size by Region (2018-2023)
2.2.3 Retinal Degenerative Disease Treatment Forecasted Market Size by Region (2024-2029)
2.3 Retinal Degenerative Disease Treatment Market Dynamics
2.3.1 Retinal Degenerative Disease Treatment Industry Trends
2.3.2 Retinal Degenerative Disease Treatment Market Drivers
2.3.3 Retinal Degenerative Disease Treatment Market Challenges
2.3.4 Retinal Degenerative Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Retinal Degenerative Disease Treatment Players by Revenue
3.1.1 Global Top Retinal Degenerative Disease Treatment Players by Revenue (2018-2023)
3.1.2 Global Retinal Degenerative Disease Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Retinal Degenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Retinal Degenerative Disease Treatment Revenue
3.4 Global Retinal Degenerative Disease Treatment Market Concentration Ratio
3.4.1 Global Retinal Degenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Retinal Degenerative Disease Treatment Revenue in 2022
3.5 Retinal Degenerative Disease Treatment Key Players Head office and Area Served
3.6 Key Players Retinal Degenerative Disease Treatment Product Solution and Service
3.7 Date of Enter into Retinal Degenerative Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Retinal Degenerative Disease Treatment Breakdown Data by Type
4.1 Global Retinal Degenerative Disease Treatment Historic Market Size by Type (2018-2023)
4.2 Global Retinal Degenerative Disease Treatment Forecasted Market Size by Type (2024-2029)
5 Retinal Degenerative Disease Treatment Breakdown Data by Application
5.1 Global Retinal Degenerative Disease Treatment Historic Market Size by Application (2018-2023)
5.2 Global Retinal Degenerative Disease Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Retinal Degenerative Disease Treatment Market Size (2018-2029)
6.2 North America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Retinal Degenerative Disease Treatment Market Size by Country (2018-2023)
6.4 North America Retinal Degenerative Disease Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Retinal Degenerative Disease Treatment Market Size (2018-2029)
7.2 Europe Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Retinal Degenerative Disease Treatment Market Size by Country (2018-2023)
7.4 Europe Retinal Degenerative Disease Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Retinal Degenerative Disease Treatment Market Size (2018-2029)
8.2 Asia-Pacific Retinal Degenerative Disease Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Retinal Degenerative Disease Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Retinal Degenerative Disease Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Retinal Degenerative Disease Treatment Market Size (2018-2029)
9.2 Latin America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Retinal Degenerative Disease Treatment Market Size by Country (2018-2023)
9.4 Latin America Retinal Degenerative Disease Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Retinal Degenerative Disease Treatment Market Size (2018-2029)
10.2 Middle East & Africa Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sucampo Pharmaceuticals
11.1.1 Sucampo Pharmaceuticals Company Detail
11.1.2 Sucampo Pharmaceuticals Business Overview
11.1.3 Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Introduction
11.1.4 Sucampo Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.1.5 Sucampo Pharmaceuticals Recent Development
11.2 Vivani Medical(Second Sight Medical)
11.2.1 Vivani Medical(Second Sight Medical) Company Detail
11.2.2 Vivani Medical(Second Sight Medical) Business Overview
11.2.3 Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Introduction
11.2.4 Vivani Medical(Second Sight Medical) Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.2.5 Vivani Medical(Second Sight Medical) Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Retinal Degenerative Disease Treatment Introduction
11.3.4 Roche Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.3.5 Roche Recent Development
11.4 ReNeuron
11.4.1 ReNeuron Company Detail
11.4.2 ReNeuron Business Overview
11.4.3 ReNeuron Retinal Degenerative Disease Treatment Introduction
11.4.4 ReNeuron Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.4.5 ReNeuron Recent Development
11.5 ReGenX Biosciences
11.5.1 ReGenX Biosciences Company Detail
11.5.2 ReGenX Biosciences Business Overview
11.5.3 ReGenX Biosciences Retinal Degenerative Disease Treatment Introduction
11.5.4 ReGenX Biosciences Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.5.5 ReGenX Biosciences Recent Development
11.6 Regeneron Pharmaceuticals
11.6.1 Regeneron Pharmaceuticals Company Detail
11.6.2 Regeneron Pharmaceuticals Business Overview
11.6.3 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Introduction
11.6.4 Regeneron Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.6.5 Regeneron Pharmaceuticals Recent Development
11.7 Orphagen Pharmaceuticals, Inc.
11.7.1 Orphagen Pharmaceuticals, Inc. Company Detail
11.7.2 Orphagen Pharmaceuticals, Inc. Business Overview
11.7.3 Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Introduction
11.7.4 Orphagen Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.7.5 Orphagen Pharmaceuticals, Inc. Recent Development
11.8 Okuvision
11.8.1 Okuvision Company Detail
11.8.2 Okuvision Business Overview
11.8.3 Okuvision Retinal Degenerative Disease Treatment Introduction
11.8.4 Okuvision Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.8.5 Okuvision Recent Development
11.9 Ocugen
11.9.1 Ocugen Company Detail
11.9.2 Ocugen Business Overview
11.9.3 Ocugen Retinal Degenerative Disease Treatment Introduction
11.9.4 Ocugen Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.9.5 Ocugen Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Retinal Degenerative Disease Treatment Introduction
11.10.4 Novartis Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.10.5 Novartis Recent Development
11.11 Nano Retina
11.11.1 Nano Retina Company Detail
11.11.2 Nano Retina Business Overview
11.11.3 Nano Retina Retinal Degenerative Disease Treatment Introduction
11.11.4 Nano Retina Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.11.5 Nano Retina Recent Development
11.12 M's Science Corporation
11.12.1 M's Science Corporation Company Detail
11.12.2 M's Science Corporation Business Overview
11.12.3 M's Science Corporation Retinal Degenerative Disease Treatment Introduction
11.12.4 M's Science Corporation Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.12.5 M's Science Corporation Recent Development
11.13 Mimetogen Pharmaceuticals Inc.
11.13.1 Mimetogen Pharmaceuticals Inc. Company Detail
11.13.2 Mimetogen Pharmaceuticals Inc. Business Overview
11.13.3 Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Introduction
11.13.4 Mimetogen Pharmaceuticals Inc. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.13.5 Mimetogen Pharmaceuticals Inc. Recent Development
11.14 Kanghong Pharma
11.14.1 Kanghong Pharma Company Detail
11.14.2 Kanghong Pharma Business Overview
11.14.3 Kanghong Pharma Retinal Degenerative Disease Treatment Introduction
11.14.4 Kanghong Pharma Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.14.5 Kanghong Pharma Recent Development
11.15 Ionis Pharmaceuticals, Inc.
11.15.1 Ionis Pharmaceuticals, Inc. Company Detail
11.15.2 Ionis Pharmaceuticals, Inc. Business Overview
11.15.3 Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Introduction
11.15.4 Ionis Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.15.5 Ionis Pharmaceuticals, Inc. Recent Development
11.16 International Stem Cell Corporation
11.16.1 International Stem Cell Corporation Company Detail
11.16.2 International Stem Cell Corporation Business Overview
11.16.3 International Stem Cell Corporation Retinal Degenerative Disease Treatment Introduction
11.16.4 International Stem Cell Corporation Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.16.5 International Stem Cell Corporation Recent Development
11.17 InFlectis BioScience
11.17.1 InFlectis BioScience Company Detail
11.17.2 InFlectis BioScience Business Overview
11.17.3 InFlectis BioScience Retinal Degenerative Disease Treatment Introduction
11.17.4 InFlectis BioScience Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.17.5 InFlectis BioScience Recent Development
11.18 Grupo Ferrer Internacional, S.A.
11.18.1 Grupo Ferrer Internacional, S.A. Company Detail
11.18.2 Grupo Ferrer Internacional, S.A. Business Overview
11.18.3 Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Introduction
11.18.4 Grupo Ferrer Internacional, S.A. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.18.5 Grupo Ferrer Internacional, S.A. Recent Development
11.19 GenSight Biologics S.A.
11.19.1 GenSight Biologics S.A. Company Detail
11.19.2 GenSight Biologics S.A. Business Overview
11.19.3 GenSight Biologics S.A. Retinal Degenerative Disease Treatment Introduction
11.19.4 GenSight Biologics S.A. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.19.5 GenSight Biologics S.A. Recent Development
11.20 Genethon
11.20.1 Genethon Company Detail
11.20.2 Genethon Business Overview
11.20.3 Genethon Retinal Degenerative Disease Treatment Introduction
11.20.4 Genethon Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.20.5 Genethon Recent Development
11.21 Genable Technologies Limited
11.21.1 Genable Technologies Limited Company Detail
11.21.2 Genable Technologies Limited Business Overview
11.21.3 Genable Technologies Limited Retinal Degenerative Disease Treatment Introduction
11.21.4 Genable Technologies Limited Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.21.5 Genable Technologies Limited Recent Development
11.22 Dompe Farmaceutici S.p.A.
11.22.1 Dompe Farmaceutici S.p.A. Company Detail
11.22.2 Dompe Farmaceutici S.p.A. Business Overview
11.22.3 Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Introduction
11.22.4 Dompe Farmaceutici S.p.A. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.22.5 Dompe Farmaceutici S.p.A. Recent Development
11.23 Caladrius Biosciences, Inc.
11.23.1 Caladrius Biosciences, Inc. Company Detail
11.23.2 Caladrius Biosciences, Inc. Business Overview
11.23.3 Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Introduction
11.23.4 Caladrius Biosciences, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.23.5 Caladrius Biosciences, Inc. Recent Development
11.24 Bayer HealthCare
11.24.1 Bayer HealthCare Company Detail
11.24.2 Bayer HealthCare Business Overview
11.24.3 Bayer HealthCare Retinal Degenerative Disease Treatment Introduction
11.24.4 Bayer HealthCare Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.24.5 Bayer HealthCare Recent Development
11.25 Astellas Pharma Inc.
11.25.1 Astellas Pharma Inc. Company Detail
11.25.2 Astellas Pharma Inc. Business Overview
11.25.3 Astellas Pharma Inc. Retinal Degenerative Disease Treatment Introduction
11.25.4 Astellas Pharma Inc. Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.25.5 Astellas Pharma Inc. Recent Development
11.26 Amarantus BioScience
11.26.1 Amarantus BioScience Company Detail
11.26.2 Amarantus BioScience Business Overview
11.26.3 Amarantus BioScience Retinal Degenerative Disease Treatment Introduction
11.26.4 Amarantus BioScience Revenue in Retinal Degenerative Disease Treatment Business (2018-2023)
11.26.5 Amarantus BioScience Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock